<DOC>
	<DOCNO>NCT00432822</DOCNO>
	<brief_summary>The aim study confirm efficacy safety BH4 treatment hyperphenylalaninemia cause phenylalanine hydroxylase deficiency patient responsive BH4 . The primary objective ass effect BH4 phenylalanine tolerance compare placebo optimal blood phenylalanine control demonstrate safety 12 month long-term treatment . Additionally population PK assess .</brief_summary>
	<brief_title>Long-Term Tetrahydrobiopterin Treatment PKU Patients 0-18 Years - Study Phenylalanine Tolerance Safety</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Female male patient , age 018 year Phenylalanine4hydroxylase ( PAH ) deficiency show mutation analysis Blood phenylalanine concentration target range dietary treatment Written consent parent legal representative Assumed availability within period study participation Patients/parents willing able follow recommend diet Use effective method contraception female patient child bear potential BH4deficiency due genetic disorder biosynthesis recycle BH4 History current evidence poor diet compliance History current evidence clinically relevant allergic idiosyncratic reaction drug food History allergic reaction BH4 excipients Positive pregnancy test ( ÃŸHCG serum ) lactating female Participation drug trial within last 30 day start study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>phenylketonuria</keyword>
	<keyword>phenylalanine hydroxylase deficiency</keyword>
	<keyword>BH4</keyword>
	<keyword>responsive</keyword>
	<keyword>tetrahydrobiopterin</keyword>
	<keyword>newborn</keyword>
	<keyword>infant</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
</DOC>